Promising results led to a sequential ongoing phase I/II clinical trial (NCT00703222) aiming to study the safety, as well as the immunological and clinical efficacy of the combined administration of SJNB-JF-IL2/Lptn and SKNLP neuroblastoma cell lines. This evidence concerns the gene XCL1 and neuroblastoma.